|
gptkb:Entresto
|
gptkb:PARADIGM-HF
|
|
gptkb:ALPN-101
|
Phase 1
|
|
gptkb:SER-155
|
Phase II
|
|
gptkb:IL2RG_gene
|
genetic testing for SCID
|
|
gptkb:Epcoritamab
|
Phase 3
|
|
gptkb:rebastinib
|
Phase 1/2
|
|
gptkb:Sanguinate
|
Phase II
|
|
gptkb:Janssen_COVID-19_Vaccine
|
gptkb:ENSEMBLE_trial
|
|
gptkb:Bravemind
|
multiple U.S. military and VA sites
|
|
gptkb:Anavex_Life_Sciences_Corp.
|
ANAVEX2-73 Phase 2b/3 for Alzheimer's disease
|
|
gptkb:NPM1_gene
|
NPM1 mutation analysis for AML diagnosis
|
|
gptkb:Sugemalimab
|
Phase 3
|
|
gptkb:Galleri_multi-cancer_early_detection_test
|
gptkb:PATHFINDER_study
|
|
gptkb:NSABP_STAR_trial
|
NCT00003906
|
|
gptkb:DMD_gene
|
genetic sequencing
|
|
gptkb:IGF1_gene
|
serum IGF-1 measurement
|
|
gptkb:RDEA119
|
Phase II
|
|
gptkb:lerociclib
|
Phase 1
|
|
gptkb:HER2_protein
|
gptkb:CISH
|
|
gptkb:FGF21
|
Pegbelfermin
|